Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS)
CNY91.40
+5.00 (+5.79%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 3 Building, No. 1999 201203
Shanghai, CN
Shanghai, CN
CEO
Baofu Zheng
Website
chemexpress.cn
IPO
2021-06-08
ISIN CNE1000051J4
Description
Shanghai Haoyuan Chemexpress Co., Ltd. is dedicated to the innovation and advancement of key compounds for the pharmaceutical industry, focusing on small molecule drugs and their essential intermediates. The company's production capabilities encompass active pharmaceutical ingredients (APIs) and their precursors, various vitamin D series substances, as well as specialized chemical building blocks and life science compounds tailored for contract research organizations (CROs). Established in 2006, its primary operational base is located in Shanghai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY91.40
+5.00 (+5.79%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.61
Float Shares
104.09M
Free Float %
49.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.08% | -0.86% | -4.05% | +0.42% | -5.58% | +0.24% | +79.91% | +36.19% | -36.74% | -36.74% | -36.74% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
91.40
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.05
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+26.4% ★ Q1'26: +20.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+17.7% ★ Q1'26: +6.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-5.6% Q1'26: -0.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+10.1% Q1'26: +11.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.2% Q1'26: +7.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.9% Q1'26: +1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.63× Q1'26: 6.34× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 4 EPS Ana. |
Dec 2027 2 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
969.23M
est: 949.74M (+2.1%)
|
1.36B
est: 1.38B (-1.6%)
|
1.88B
est: 1.88B (+0.1%)
|
2.27B
est: 2.27B (+0.2%)
|
2.87B
est: 2.85B (+0.5%)
|
3.57B
3.51B – 3.62B
+25.0% YoY
|
4.38B
4.21B – 4.55B
+22.8% YoY
|
5.34B
5.19B – 5.49B
+21.9% YoY
|
| EBITDA |
237.82M
est: 171.32M (+38.8%)
|
254.64M
est: 249.01M (+2.3%)
|
250.23M
est: 338.95M (-26.2%)
|
406.52M
est: 402.11M (+1.1%)
|
407.87M
est: 506.23M (-19.4%)
|
632.80M
622.69M – 642.92M
+25.0% YoY
|
777.25M
746.83M – 807.67M
+22.8% YoY
|
947.64M
920.44M – 974.83M
+21.9% YoY
|
| EBIT |
222.03M
est: 142.46M (+55.9%)
|
218.15M
est: 207.06M (+5.4%)
|
166.80M
est: 281.86M (-40.8%)
|
287.94M
est: 320.03M (-10.0%)
|
289.29M
est: 402.89M (-28.2%)
|
503.63M
495.58M – 511.68M
+25.0% YoY
|
618.59M
594.38M – 642.80M
+22.8% YoY
|
754.20M
732.55M – 775.84M
+21.9% YoY
|
| Net Income |
190.98M
est: 198.49M (-3.8%)
|
193.64M
est: 230.67M (-16.1%)
|
127.45M
est: 121.49M (+4.9%)
|
201.59M
est: 180.71M (+11.6%)
|
239.81M
est: 286.11M (-16.2%)
|
349.28M
335.89M – 362.68M
+22.1% YoY
|
464.35M
436.37M – 492.32M
+32.9% YoY
|
613.42M
590.54M – 636.31M
+32.1% YoY
|
| SGA |
182.54M
est: 182.71M (-0.1%)
|
277.64M
est: 265.55M (+4.6%)
|
376.21M
est: 361.48M (+4.1%)
|
443.37M
est: 389.56M (+13.8%)
|
204.68M
est: 490.43M (-58.3%)
|
613.05M
603.25M – 622.85M
+25.0% YoY
|
752.99M
723.52M – 782.45M
+22.8% YoY
|
918.05M
891.71M – 944.40M
+21.9% YoY
|
| EPS |
1.07
est: 0.95 (+13.2%)
|
0.95
est: 1.10 (-13.5%)
|
0.61
est: 0.58 (+5.4%)
|
0.96
est: 0.85 (+12.5%)
|
1.13
est: 1.44 (-21.5%)
|
1.63
1.59 – 1.71
+13.4% YoY
|
2.23
2.06 – 2.32
+36.3% YoY
|
2.90
2.79 – 3.00
+30.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
299.49M
OE per share TTM
1.40
Owner's Yield
1.96%
Maintenance CapEx ratio
19.60%
Maint CapEx / Avg PPE
41.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 564.9K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 18.7K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 42.2K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.08M | 0.06% |
| 5 | Vanguard Total International Stock ETF VXUS | 0.00% | 2.28M | 0.05% |
| 6 | Vanguard ESG International Stock ETF VSGX | 0.00% | 21.9K | 0.10% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 161.8K | 0.06% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 3.3K | 0.22% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 10.1K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 5.4K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
80.9K
Shares Outstanding
212.10M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Baofu Zheng | Chairman & GM | — | male |
| Kuei Mei | Core Technical Staff | — | male |
| Min Li | Chief Financial Officer & Accounting Supervisor | — | female |
| Qiang Gao | Deputy GM & Director | — | male |
| Weihong Shen | Board Secretary | — | female |
| Zhiguo Zhou | Core Technical Staff | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688131.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
